BIO
Bio-Rad Laboratories
Is BIO Halal?
Life-science instruments and diagnostics are generally permissible, subject to investment and end-use review.
What You Should Know
Bio-Rad's March 31, 2026 filing shows debt/assets of 12.29%, liquidity/assets of 15.98%, receivables plus cash/assets of 9.53% and disclosed interest/investment income/revenue of 3.55%. Its life-science and clinical-diagnostics products generally support research and health, but product ingredients, laboratory workflows, customer end uses and substantial investments are not allocated into a universal prohibited-revenue numerator.
⚠️ Concerns
- •Diagnostics and research workflows require product, patient-safety and research-ethics review
- •Customer end-use and government or pharmaceutical exposure is not separately quantified
- •Short-term investments and equity holdings require asset-composition review
- •Financial ratios pass the examined asset-based screens, but business classification remains incomplete
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-14.
1,203.4 / 9,790
1,564.7 / 9,790
933.4 / 9,790
21 / 592.1
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 12.29%, liquidity/assets is 15.98%, receivables plus cash/assets is 9.53% and disclosed interest/investment income/revenue is 3.55%, below the examined limits; activity classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 12.29%, liquidity/assets is 15.98% and receivables plus cash/assets is 9.53%, below the examined MSCI total-assets limits; activity classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
The examined ratios pass at debt/assets 12.29% and liquidity/assets 15.98%; activity classification remains incomplete and this is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored and business classification remains incomplete, so market-cap methods are not estimated from a current spot price.
Business-activity disclosure
Bio-Rad supplies life-science research products, clinical diagnostics, quality-control systems and laboratory workflows. These activities generally support research and health, while product ingredients, diagnostics, customer end uses and investment exposure require continuing qualitative review.
Limitation: The filing does not allocate revenue into a universal prohibited-activity numerator for laboratory workflows, diagnostics, customer end uses or substantial investments.
Purification
Bio-Rad discloses $21.0 million of interest and investment income but does not prescribe a scholar-approved purification percentage; the disclosed ratio is evidence for the income screen, not a complete purification prescription.
Inputs, assumptions and primary sources
- Amounts are USD millions from Bio-Rad's March 31, 2026 Form 10-Q and rounded to the nearest tenth where disclosed.
- Debt includes current maturities of long-term debt and notes payable of $400.5 million plus long-term debt of $802.9 million; operating leases are excluded.
- Cash and cash equivalents are $507.2 million and short-term investments are $1,057.5 million.
- Accounts receivable, net are $426.2 million and first-quarter net sales are $592.1 million; disclosed interest and investment income is $21.0 million.
- The filing does not allocate product, customer or end-use revenue into a universal prohibited-activity numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →